PubMed · 148935
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
V V Kakkar, M F Scully. 1978. Thrombolytic therapy.. https://doi.org/10.1093/oxfordjournals.bmb.a071491
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Citrate determination in coagulation blood samples sometimes end considerable deviations from the prescribed end concentration. Only a part of these samples can be recognized in the laboratory by simple inspection, in the undiscovered cases faulty results must be reckoned with. The citrate end concentration is more reproducible under routine conditions when a special sampling apparatus (Citrate-Monocuvette) is used.
Clotting analysis in 30 patients with bleeding complications in malignant hematological diseases revealed the following troubles: The global tests, Quick's index and partial thromboplastin time markedly differed from normal. Activity of clotting factors revealed hypo- or hyperfibrinogenemia, disturbances of the prothrombin complex (factors II, VII, IX and X), decrease of factors V, VIII, XII. Factor XI (= PTA) was not diminished in any case. Regarding the fibrin-stabilizing factor (factor XIII), its activity was significantly decreased in 30 patients with solid tumors and in 30 patients with hemoblastoses. Faulty clotting balance was characterized by hyperfibrinolysis or disseminated intravascular coagulation (DIC) accompanied by reactive hyperfibrinolysis. About one quarter of the patients with malignant disturbances of the hematopoetic system demonstrated (mostly amegacaryocyte) thrombocytopenia. Finally, treatment of bleeding complications in malignant neoplastic diseases is pointed out.
Explore the source record for details and available documents.